August 5, 2024

Supplementary Documents of Consolidated
Financial Results for the First Quarter of FY2024(from April 1, 2024 to March 31, 2025)

Securities code：4886 (TSE)
ASKA Pharmaceutical Holdings Co., Ltd.

Highlight
1Q FY2024 (Consolidated)✓ 16.3 billion yen, up 2.1% YOY
Net sales

Increased sales due to growth in pharmaceutical and veterinary pharmaceutical business.

8.1 billion yen, improved 3.4 percentage points YOY✓
Cost of sales
Improved product mix due to growth of Brand-name drugs, cost reduction efforts, etc.
SG&A
expenses✓ 6.4 billion yen, up 3.3 percentage points YOY

Operatingprofit✓ 1.7 billion yen, up 3.1% YOY

Impacted by increased costs associated with R&D progress, etc.

Increased due to increases in sales and gross profit

FY2024 Consolidated Financial Forecast *No changes from the forecast previously announced
Performance ✓ Net sales 63.0 billion yen, up 0.2% YOYforecast✓ Operating profit 6.7 billion yen, up 3.1% YOY
2

Statements of Income (Consolidated)(Millions of yen)

FY2023 Apr - JunActualFY2024 Apr - JunActualActual +/-Growth +/-Net sales

16,023

16,352329

2.1%

Operating profit

1,704

1,758

53

3.1%

Ordinary profit

1,809

1,813

30.2%

Profit attributable toowners of parent

1,428

1,273-155-10.9%

Major factors for increases and decreases
 While the future prospects remained uncertain as a result of factors such as the ongoing geopolitical risks, decreased value of the yen on
international currency markets, and rising prices of energy and raw materials, net sales increased due to the growth of the pharmaceuticalbusiness and veterinary pharmaceutical business.
 On the profit front, operating profit and ordinary profit increased due to cost improvement efforts despite increases in R&D expenses, etc.
 Profit attributable to owners of parent decreased by 10.9% YoY, due to an increase in income taxes as well as reaction to the recording ofa gain on sales of investment securities as extraordinary income in the previous fiscal year.

3Net Sales by Business (Consolidated)(Millions of yen)

FY2023 Apr - JunActualFY2024 Apr - JunActualBreakdown

Actual +/-Growth +/-Pharmaceuticalbusiness

14,42014,49388.6%

730.5%

Animal healthBusiness

1,560

1,800

11.0%

240

15.4%

4257

0.4%

1537.6%

16,023

16,352100.0%

329

2.1%

Other businesses
TotalMajor factors for increased sales
 The pharmaceutical business, which focuses on the three fields of internal medicine, obstetrics and gynecology, andurology, showed favorable trends overall despite the impact of the periodical NHI drug price revisions. The obstetrics
and gynecology field were driven by the growth in RELUMINA and DroEthi. In the internal medicine field, Sales ofTHYRADIN and RIFXIMA also grew steadily.
 In the animal health business, sales of veterinary pharmaceutical and feed additives were strong, resulting in a 15.4%
increase YOY.

4

Sales of Main Products (Pharmaceutical Business)
Area

Category

Internal Medicine

ActualFY2024YOY

Forecast

Reference
YOY

InitialForecast

Notes

2,599

2,230-14.2%

8,447-12.0%

8,626

The NHI drug price declined, but sales volume
remained almost same

Brand-name

THYRADIN

2,062

2,076

0.7%

8,018

2.0%

8,018

Slight increase due to disease awarenessactivities, etc.

Brand-nameRIFXIMA

1,525

1,645

7.9%

6,117

4.3%

6,117

Sales grew steadily as the Guideline
penetrated

Brand-name

MERCAZOLE

398403

1.2%

1,510

-0.7%

1,510

Progress as expected

225

209

-7.3%

806

-4.1%

806

Progress as expected

RELUMINA

2,576

2,644

2.6%

10,945

10.5%

11,251

Focused on expanding our share in theendometriosis market.

DroEthi

1,401

1,743

24.5%

6,416

4.8%

5,990

The NHI drug price down but sales volume up
more than expected

Generic

Brand-name

Obstetrics and Gynecology

ActualFY2024Apr - Jun

CANDESARTAN * 1AG

Urology

Products(generic name)

FY2023Apr - Jun

(Millions of yen)

Generic(candesartan)(levothyroxine)(rifaximin)(thiamazole)

AMLODIPINE(amlodipine)(relugolix)(norethisterone/ethinylestradiol)AG

FREWELL

832

771

-7.4%

3,101-6.1%

3,101

The NHI drug price down, but sales volume
increased.

Brand-name

LUTEUM

440

556

26.3%

2,171

7.0%

2,106

Sales increased due to external factors, etc.

Brand-name

ANGE

194

174-10.2%

790

9.0%

790

Decreased due to switch to other products

Brand-name

MAGSENT * 2154

192

24.7%

665

-5.8%

665

Exceeded our expectation

1,192

1,021

-14.3%

3,962-10.6%

3,962

Generic(drospirenone/ethinylestradiol)(progesterone)(levonorgestrel/ethinylestradiol)(magnesium sulfate)

LEUPRORELIN * 3(leuprorelin)* 1 Including compounding agents* 3 1.88mg formulation is only for gynecological indications but combined with 3.75mg formulation* 2 Total value of magnesium sulfate preparation

Impacted by decreased NHI drug price andbrand-name drugs
5Sales by Major Business Field (Animal Health Business)(Millions of yen)

Business field

FY2023 Apr – JunActualFY2024 Apr - JunActualFY2024YOYForecast

YOY

Feed additives
Mixed feed
Feed materials

965

1,160

20.2%

4,031-0.2%

Veterinary
pharmaceuticals

576625

8.5%

2,534

1.9%

(livestock and fisheries + *CA)

Major factors for increased sales
 In the area of feed additives and other products, sales grew mainly in amino acid feed additives, reflecting strong
demand for amino acids.
 In the veterinary pharmaceutical field, sales of livestock and fisheries products and companion animal pharmaceuticalsremained strong.
* Companion Animal
6

Sales Proportion of Brand-name Drugs■ Brand-name drugs ■ Generic drugs

1Q FY2023

47.0%

53.0%

1Q FY2024
45.2%

54.8%

The product mix improved due to growth in RELUMINA, RIFXIMA, and THYRADIN, resulting in a 1.8 percentage point
increase in the ratio of brand-name drugs to sales, despite the significant growth in sales of DroEthi, a generic drug.

7

R&D Status
As of August 5, 2024

Trend of R&D expenses（Millions of yen）
(Forecast)

5,575

4,227

4,728

Development code (Generic name) / Indication
LF111 (drospirenone)
Contraception

Filed(Option agreement)
Treatment for PMS/PMDD

Ph II(IIT *1)

AKP-022 (Relugolix combination tablet)
Uterine fibroids

Ph I / II

TRM-270 (adhesion barrier)(Gastroenterology and Ob/Gyn)

Ph III

L-105 (rifaximin)
Hepatic encephalopathy (pediatrics)
AKP-009 (ludaterone acetate)
Benign prostatic hyperplasia

1,652(1Q)

FY2021

FY2022

FY2022
FY2023

FY2023
FY2024Phase

AKP-017（transnasal testosterone）(Urology)

Approved

Ph II*2
Preparing forclinical trials*1 Investigator-initiated clinical trial*2 Phase I trial are conducted again.

8